Anthralin/dithranol in dermatology

International Journal of Dermatology

Volumn 53, Issue 10, 2014, Pages e449-e460

  Sehgal, Virendra N ^a   Verma, Prashant ^b   Khurana, Ananta ^b  

^a Sehgal Nursing Home   (India)

^b UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DITHRANOL;

ALOPECIA AREATA; ARTICLE; DERMATOLOGY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; ERYTHEMA; HUMAN; IRRITANT DERMATITIS; NAIL PSORIASIS; PHARMACOLOGY; PSORIASIS; PSORIASIS VULGARIS; SEBORRHEIC DERMATITIS; SKIN DISEASE; TOPICAL TREATMENT; SKIN DISEASES;

ANTHRALIN; HUMANS; SKIN DISEASES;

EID: 84907813137     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05611.x     Document Type: Article

References (93)

1. Barth J. Introduction of anthralin into dermatology. Int J Dermatol 1992; 31: 67.
2. Scholz A, Kadner H. 75 years of Cignolin. Hautarzt 1991; 42: 775-778.
3. Galewsky E. Über Cignolin, ein Ersatzpräparat des Chrysarobins. Dermatol Wochenschr 1910; 62: 116-127.
4. Shekelle PG, Woolf SH, Eccles M, et al. Clinical guidelines: developing guidelines. BMJ 1999; 318: 593-596.
5. McGill A, Frank A, Emmett N, et al. The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J 2005; 19: 1012- 1014.
6. Schimidt KN, Podda M, Packer L, et al. Anti-psoriatic drug anthralin activates transcription factor NF-Kappa B in murine keratinocytes. J Immunol 1996; 156: 4514- 4519.
7. Diezel W, Meffert H, Sonnichsen N. Study on the mode of action of dithranol-induced lipid peroxidation and enzyme inhibition. Dermatologica 1975; 150: 154-162.
8. Mrowietz U, Jesat H, Schwarz A, et al. Anthralin (Dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF alpha, but not IL-1. Br J Dermatol 1997; 136: 542-547.
9. Kavanagh GM, Burton JL, Donnel VO. Effects of dithranol on neutrophil superoxide generation in patients with psoriasis. Br J Dermatol 1996; 134: 234-237.
10. Gottlieb AB, Khandke L, Krave JF, et al. Anthralin decreases keratinocyte TGF-alpha expression and EGFreceptor binding in vitro. J Invest Dermatol 1992; 98: 680-685.
11. Kemeny L, Michael G, Arenberger P, et al. Downregulation of epidermal growth factor receptors by dithranol. Acta Derm Venereol 1993; 73: 37-40.
12. Mrowietz U, Falsafi M, Schorder JM, et al. Inhibition of human monocyte functions by anthralin. Br J Dermatol 1992; 127: 382-386.
13. Kemeny L, Gross E, Arenberger P, et al. Dithranolinduced down regulation of 12 (s)-hydroxyeicosatetraenoic acid [12(5)-HETE] receptors in a human epidermal cell line. Arch Dermatol Res 1991; 283: 333-336.
14. Schroder JM. Anthralin (1,8-dihydroxyanthrone) is a potent inhibitor of leukotriene production and LTB4-omega oxidation by human neutrophils. J Invest Dermatol 1986; 87: 624-629.
15. Schalleuter KV, Pittelknow MR. Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. A new mode of action of this drug. Arch Dermatol 1987; 123: 1494-1498.
16. Yamamoto T, Nishioka K. Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy. Skin Pharmacol Appl Skin Physiol 2003; 16: 50-58.
17. Tang L, Sundberg JP, Lui H, et al. Old wine in new bottles: reviving old therapies for alopecia areata using rodent models. J Investig Dermatol Symp Proc 2003; 8: 212-216.
18. Whitefield M. Pharmaceutical formulations of anthralin. Br J Dermatol 1981; 105: 28-32.
19. Bellis D, Seville RH, Smith JF. Dithranol with salicylic acid in a stiff paraffin base for the treatment of psoriasis. J Clin Pharm Ther 1978; 3: 7-11.
20. Hulsebosch HJ, Ponec-Waelsch M. The interaction of anthralin, salicylic acid and zinc oxide in pastes. Dermatologica 1972; 144: 287-293.
21. Ponec-Waelsch M, Hulsebosch HJ. Further studies on the interaction between anthralin salicylic acid and zinc oxide in pastes. Arch Dermatol Forsch 1974; 249: 141-152.
22. Mustakallio KK. The history of dithranol and related hydroxyanthrones, their efficacy, side effects, and different regimens employed in the treatment of psoriasis. A review. Acta Derm Venereol Suppl 1992; 172: 7-9.
23. Mahrle G. Dithranol. Clin Dermatol 1997; 15: 723-737.
24. Prins M, Swinkels OQ, Bouwhuis S, et al. Dithranol in a cream preparation: disperse or dissolve? Skin Pharmacol Appl Skin Physiol 2000; 13: 273-279.
25. Gehring W, Ghyczy M, Gloor M, et al. Enhancement of the penetration of dithranol and increase of effect of dithranol on the skin by liposomes. Arzneimittelforschung 1992; 42: 983-985.
26. Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm 2001; 228: 43-52.
27. Gidwani SK, Singnurkar PS. Composition for Delivery of Dithranol. India: European Patent Office, 2003: 1-14.
28. Saraswat A, Agarwal R, Kaur I, et al. Fabric-staining properties and washability of a novel liposomal dithranol formulation. J Dermatolog Treat 2002; 13: 119-122.
29. Saraswat A, Agarwal R, Katare OP, et al. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatolog Treat 2007; 18: 40-45.
30. Agarwal R, Saraswat A, Kaur I, et al. A novel liposomal formulation of dithranol for psoriasis: preliminary results. J Dermatol 2002; 29: 529-532.
31. Anonymous. Biotech product and process development and commercialization awards. In: DBT. New Delhi: Government of India, 2007: 1-5.
32. Anonymous. Biotech product and process development and commercialization awards, Ministry of Science and Technology. In: DBT. New Delhi: Government of India; 2006: 16-19.
33. Ingram JT. The approach to psoriasis. Br Med J 1953; 2: 591-594.
34. Ross JB. Psoriasis - the Ingram method of treatment. Cutis 1969; 5: 1261-1265.
35. Swinehart JM, Lowe NJ. UVABA therapy for psoriasis. Efficacy with shortened treatment times with the combined use of coal tar, anthralin, and metal halide ultraviolet machines. J Am Acad Dermatol 1991; 24: 594-597.
36. Ashton RE, Andre P, Lowe NJ, et al. Anthralin: historical and current perspectives. J Am Acad Dermatol 1983; 9: 173-192.
37. Lowe NJ, Ashton RE, Koudsi H, et al. Anthralin for psoriasis: short-contact anthralin therapy compared with topical steroid and conventional anthralin. J Am Acad Dermatol 1984; 10: 69-72.
38. Schaefer H. Short-contact therapy. Arch Dermatol 1985; 121: 1505-1509.
39. Schaefer H, Farber EM, Goldberg L, et al. Limited application period for dithranol in psoriasis - preliminary report on penetration and clinical efficacy. Br J Dermatol 1980; 102: 571-573.
40. Hartman M, Prins M, Swinkels OQ, et al. Costeffectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment. Br J Dermatol 2002; 147: 538-544.
41. Schwarz T, Gschnait F. Anthralin minute entire skin treatment. A new outpatient therapy for psoriasis. Arch Dermatol 1985; 121: 1512-1515.
42. Duschet P, Schwarz T, Pusch M, et al. Anthralin minute entire skin treatment: a follow-up and comparison with methoxsalen plus ultraviolet light. Arch Dermatol 1987; 123: 428-429.
43. McBride SR, Walker P, Reynolds NJ. Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. Br J Dermatol 2003; 149: 1259-1265.
44. Kirkup ME, Sabroe RA, Kavanagh GM, et al. Twicedaily vs. once-daily inpatient dithranol for psoriasis. Clin Exp Dermatol 2002; 27: 695-699.
45. De Bersaques J. A retrospective study of the inpatient treatment of psoriasis with dithranol. Dermatologica 1987; 175: 64-68.
46. Statham BN, Ryatt KS, Rowell NR. Short-contact dithranol therapy - a comparison with the Ingram regime. Br J Dermatol 1984; 110: 703-708.
47. de Korte J, van der Valk PG, Sprangers MA, et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: qualityof-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. Br J Dermatol 2008; 158: 375-381.
48. Wall AR, Poyner TF, Menday AP. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. Br J Dermatol 1998; 139: 1005-1011.
49. Hutchinson PE, Marks R, White J. The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology 2000; 201: 139-145.
50. Poyner TF, Menday AP, Williams ZV. Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol. J Eur Acad Dermatol Venereol 2000; 14: 153- 158.
51. Vella Briffa D, Greaves MW, Warin AP, et al. Relapse rate and long-term management of plaque psoriasis after treatment with photochemotherapy and dithranol. Br Med J 1981; 282: 937-940.
52. Monastirli A, Georgiou S, Pasmatzi E, et al. Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis. Skin Pharmacol Appl Skin Physiol 2002; 15: 246-251.
53. Swinkels OQ, Prins M, Kucharekova M, et al. Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid. Br J Dermatol 2002; 146: 621-626.
54. Schulze HJ, Schauder S, Mahrle G, et al. Combined taranthralin versus anthralin treatment lowers irritancy with unchanged antipsoriatic efficacy. Modifications of shortcontact therapy and Ingram therapy. J Am Acad Dermatol 1987; 17: 19-24.
55. Przybilla B, Kaudewitz P, Bieber K. Urea in combination with dithranol in treating psoriasis vulgaris. Hautarzt 1989; 40: 54-57.
56. Sander P, Happe M, Stücker M, et al. Tazarotene increases the antipsoriatic effect of dithranol in chronic psoriasis. Hautarzt 1999; 50: 723-727.
57. Wulff-Woesten A, Ohlendorf D, Henz BM, et al. Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacol Physiol 2004; 17: 91-97.
58. Wright S, Mann RJ. Comparison of a cream containing 0.1% dithranol in a 17% urea base (Psoradrate) with coal tar pomade in the treatment of scalp psoriasis. Clin Exp Dermatol 1985; 10: 375-378.
59. Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol 1998; 25: 231-233.
60. Zvulunov A, Anisfeld A, Metzker A. Efficacy of shortcontact therapy with dithranol in childhood psoriasis. Int J Dermatol 1994; 33: 808-810.
61. de Jager ME, van de Kerkhof PC, de Jong EM, et al. Dithranol therapy in childhood psoriasis: unjustifiably on the verge of falling into oblivion. Dermatology 2010; 220: 329-332.
62. de Jager ME, de Jong EM, van de Kerkhof PC, et al. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010; 62: 1013-1030.
63. Tauscher AE, Fleischer AB Jr, Phelps KC, et al. Psoriasis and pregnancy. J Cutan Med Surg 2002; 6: 561-570.
64. Nelson DA, Spielvogel RL. Anthralin therapy for alopecia areata. Int J Dermatol 1985; 24: 606-607.
65. Bolduc C, Shapiro J. The treatment of alopecia areata. Dermatol Ther 2001; 14: 306-316.
66. Wasserman D, Guzman-Sanchez DA, Scott K, et al. Alopecia areata. Int J Dermatol 2007; 46: 121-131.
67. Schmoeckel C, Weissmann I, Plewig G, et al. Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 1979; 115: 1254-1255.
68. Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987; 123: 1491-1493.
69. Torchia D, Schachner LA. Bilateral treatment for alopecia areata. Pediatr Dermatol 2010; 27: 415-416.
70. Narahari SR. Comparative efficacy of topical anthralin and intralesional triamcinolone in the treatment of alopecia areata. Indian J Dermatol Venereol Leprol 1996; 62: 348-350.
71. Das S, Ghorami RC, Chatterjee T, et al. Comparative assessment of topical steroids, topical tretinoin (0.05%) and dithranol paste in alopecia areata. Indian J Dermatol 2010; 55: 148-149.
72. Fiedler VC, Wendrow A, Szpunar GJ, et al. Treatmentresistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol 1990; 126: 756-759.
73. Flindt-Hansen H, Tikjøb G, Brandrup F. Wart treatment with anthralin. Acta Derm Venereol 1984; 64: 177-179.
74. Hjorth N, Madsen K, Nørgaard M. Anthralin stick (Anthraderm) in the treatment of mosaic warts. Acta Derm Venereol 1986; 66: 181-182.
75. Rulo HF, van de Kerkhof PC. Treatment of inflammatory linear verrucous epidermal nevus. Dermatologica 1991; 182: 112-124.
76. de Mare S, van de Kerkhof PC, Happle R. Dithranol in the treatment of inflammatory linear verrucous epidermal nevus. Acta Derm Venereol 1989; 69: 77-80.
77. Wölbling RH, Schöfer H, Milbradt R. Treatment of seborrheic dermatitis with low-dosage dithranol. Hautarzt 1985; 36: 529-530.
78. Ludolph-Hauser D, Michelsen S, Korting HC. Pustular dermatitis after administration of a too highly concentrated dithranol ointment in seborrhoea. Hautarzt 1998; 49: 781-783.
79. Bruner CR, Feldman SR, Ventrapragada M, et al. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003; 9: 2.
80. Silverman A, Menter A, Hairston JL. Tars and anthralins. Dermatol Clin 1995; 13: 817-833.
81. Maurice PD, Greaves MW. Relationship between skin type and erythemal response to anthralin. Br J Dermatol 1983; 109: 337-341.
82. Parslew R, Friedmann PS. The irritancy of anthralin is inhibited by repeat applications of a subirritant concentration. Br J Dermatol 1999; 141: 469-474.
83. Swinkels OQ, Prins M, Tosserams EF, et al. The influence of a topical corticosteroid on short-contact high-dose dithranol therapy. Br J Dermatol 2001; 145: 63-69.
84. Seville RH. Relapse rate of psoriasis worsened by adding steroids to a dithranol regime. Br J Dermatol 1976; 95: 643-646.
85. Lawrence CM, Shuster S. Mechanism of anthralin inflammation. Dissociation of response to clobetasol and indomethacin. Br J Dermatol 1985; 113: 107-115.
86. Lawrence CM, Shuster S. Mechanism of anthralin inflammation. Effect of pretreatment with glucocorticoids, anthralin and removal of stratum corneum. Br J Dermatol 1985; 113: 117-122.
87. van de Kerkhof PC, Timmerman MG. The effect of clobetasol-17-propionate and crude coal tar on dithranolinduced inflammation. A clinical and biochemical study. Acta Derm Venereol 1990; 70: 434-437.
88. Juhlin L. Factors influencing anthralin erythema. Br J Dermatol 1981; 105: 87-91.
89. Ramsay B, Lawrence CM, Bruce JM, et al. The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol 1990; 23: 73-76.
90. Lawrence CM, Shuster S, Collins M, et al. Reduction of anthralin inflammation by potassium hydroxide and Teepol. Br J Dermatol 1987; 116: 171-177.
91. Finnen MJ, Lawrence CM, Shuster S. Inhibition of dithranol inflammation by free-radical scavengers. Lancet 1984; ii: 1129-1130.
92. Wang JC, Krazmien RJ, Dahlheim CE, et al. Anthralin stain removal. J Am Acad Dermatol 1986; 15: 951-955.
93. Ippen H. Basic questions on toxicology and pharmacology of anthralin. Br J Dermatol 1981; 105: 72-76.